Get the Stockscreener App
2.77
1.07%
-0.03
Valion Bio Inc stock is traded at $2.77, with a volume of 71,471.
It is down -1.07% in the last 24 hours and up +733.58% over the past month.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
See More
Previous Close:
$2.80
Open:
$2.9
24h Volume:
71,471
Relative Volume:
0.01
Market Cap:
$11.50M
Revenue:
$232.00K
Net Income/Loss:
$-12.13M
P/E Ratio:
-0.3097
EPS:
-8.9454
Net Cash Flow:
$-10.29M
1W Performance:
+2,191%
1M Performance:
+733.58%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.72
$2.9893
1-Week Range:
$2.70
$3.87
52-Week Range:
$0.1116
$3.87
Valion Bio Inc Stock (VBIO) Company Profile
Name
Valion Bio Inc
Sector
Industry
Phone
(888)276-6888
Address
1305 E. HOUSTON STREET, SAN ANTONIO
Compare VBIO vs PSNYW, GOODO, SHMD, DWLD, QQQE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.00 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
5.00 | 394.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.15 | 315.90M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.39 | 0 | 0 | 0 | 0 | 0.00 |
QQQE
Direxion NASDAQ-100 Equal Weigh
|
120.75 | 0 | 0 | 0 | 0 | 0.00 |
Valion Bio Inc Stock (VBIO) Latest News
3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan
Valion Bio Terminates CEO in Change of Corporate Leadership - Minichart
Form 8K Valion Bio Inc For: 17 August By Investing.com - Investing.com Nigeria
Valion Bio appoints new COO, terminates CEO, and announces funding agreements - Investing.com Canada
Valion Bio Secures New Series B Preferred Financing - TipRanks
Valion Bio Cash Plunges to $2.1M, Flags Going-Concern Risk - Minichart
Valion Bio (VBIO) investor group reports 1.74M shares, capped at 9.9% stake - Stock Titan
Valion Bio (OTC: VBIO) faces going concern risk and Nasdaq bid price warning - Stock Titan
Valion Bio, Inc. Q2 2026: Net loss $7.1M, EPS $(2.17) — 10-Q Summary - TradingView
Valion Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entolimod Could Receive Its First National Registration in Ukraine - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Valion Bio, Inc. (VBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Valion Bio Inc. (VBIO) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall - Yahoo Finance
Valion Bio begins safety study for radiation injury drug - Investing.com
Valion Bio begins safety study for radiation injury drug By Investing.com - Investing.com Canada
News by ACCESS Newswire on TradingView, 2026-08-12 - TradingView
Valion Bio Plans Mouse Study After Lethal Radiation Exposure - Stock Titan
Valion Bio, Inc. (OTC: VBIO) investors file 13D/A and outline $9M preferred stock plan - Stock Titan
Valion Bio, Inc.Common stock (Nasdaq:VBIO) Stock Quote - FinancialContent
Insiders Who Sold Valion Bio Missed Out On 19% Stock Increase - webull.com
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - tradingview.com
3i, LP Issues Letter to Valion Bio, Inc - marketscreener.com
Valion Bio Inc (NASDAQ: VBIO) Share Price, VBIO Stock News, VBIO Share Price & Updates - Kalkine
Murchinson Ltd. Acquires 440,242 Shares in Valion Bio Inc. - GuruFocus
Ukraine could issue an Entolimod decision in as few as 45–60 days - Stock Titan
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway - Morningstar
Planned cancer trial will test whether Entolimod protects marrow - Stock Titan
Sheba Medical Center to evaluate Valion Bio’s Entolimod in trial By Investing.com - Investing.com Canada
Sheba Medical Center to evaluate Valion Bio’s Entolimod in trial - Investing.com
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market - PR Newswire
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
Form S-1 Valion Bio Inc For: 17 July By Investing.com - Investing.com Nigeria
Valion Bio Offering Up to 29.4M Shrs and Up to 29.4M Common Warrants - Moomoo
IPO Databook: Valion Bio (VBIO US)Jul 2026 - Smartkarma
Form S-1 Valion Bio Inc For: 17 July - Investing.com India
Form DEF 14A Valion Bio Inc For: 17 July By Investing.com - Investing.com Canada
Valion Bio (OTC: VBIO) asks holders to OK 1-for-5 to 1-for-50 reverse split - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Valion Bio advances Entolimod platform and manufacturing scale-up - The Globe and Mail
Valion Bio, Inc. Expands Manufacturing Capacity and Pursues Government and International Preparedness Opportunities - marketscreener.com
Valion Bio reports 200-fold Entolimod scale-up, advances govt engagement and oncology plans - TradingView
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion - Fidelity Investments
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Valion Bio Reports Entolimod Scale-Up Equal to ~1.3M Potential Human Doses - Stock Titan
Valion Bio (VIBO) Emerging Growth Conference 89 Summary - Quartr
Enterprise value to EBITDA forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Form PRE 14A Valion Bio Inc For: 7 July By Investing.com - Investing.com Nigeria
[PRE 14A] Valion Bio, Inc. Preliminary Proxy Statement - Stock Titan
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS - AOL.com
Valion Bio Inc Stock (VBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Valion Bio Inc Stock (VBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Valauri Christina Rizopoulos | Director |
Apr 01 '26 |
Buy |
0.95 |
19,000 |
18,008 |
19,000 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):